ReviewCancer medicine2016
Progress in the clinical detection of heterogeneity in breast cancer.
Review in Cancer medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Upregulated miR‑203a‑3p and its potential molecular mechanism in breast cancer: A study based on bioinformatics analyses and a comprehensive meta‑analysis.Molecular medicine reports · 2018Pooled it
- Latent class analysis of conventional ultrasound features: a novel approach to predicting non-response to neoadjuvant chemotherapy in breast cancer.Frontiers in oncology · 2026Article
- Synchronous bilateral breast cancer with heterogeneous hormone receptor status: a case report.Journal of surgical case reports · 2024Article
- Suppressing mitochondrial inner membrane protein (IMMT) inhibits the proliferation of breast cancer cells through mitochondrial remodeling and metabolic regulation.Scientific reports · 2024Article
- Profiling of serum metabolome of breast cancer: multi-cancer features discriminate between healthy women and patients with breast cancer.Frontiers in oncology · 2024Article
- Synchronous Bilateral Breast Cancer With Discordant Receptor Status: Treating One Patient but Two Diseases.World journal of oncology · 2023Article
- Antitumor therapy for breast cancer: Focus on tumor-associated macrophages and nanosized drug delivery systems.Cancer medicine · 2023Review
- Metabolic abnormalities and survival among patients with non-metastatic breast cancer.BMC cancer · 2022Article
- Genetic heterogeneity: Challenges, impacts, and methods through an associative lens.Genetic epidemiology · 2022Review
- A comparison of Chinese multicenter breast cancer database and SEER database.Scientific reports · 2022Article
- The prognostic significance of a novel ferroptosis-related gene model in breast cancer.Annals of translational medicine · 2022Article
- Estrogen Receptor and Claudin-6 Might Play Vital Roles for Long-Term Prognosis in Patients With Luminal A Breast Cancer Who Underwent Neoadjuvant Chemotherapy.Frontiers in oncology · 2022Article
- Long Non-Coding RNA NORAD Inhibits Breast Cancer Cell Proliferation and Metastasis by Regulating miR-155-5p/SOCS1 Axis.Journal of breast cancer · 2021Article
- Liquid Biopsy in the Clinical Management of High-Grade Serous Epithelial Ovarian Cancer-Current Use and Future Opportunities.Cancers · 2021Review
- Distribution and influence of the 21-gene recurrence score on chemotherapy decision-making in special type of breast cancer.American journal of cancer research · 2021Article
- Intertumoral Heterogeneity of Primary Breast Tumors and Synchronous Axillary Lymph Node Metastases Reflected in IHC-Assessed Expression of Routine and Nonstandard Biomarkers.Frontiers in oncology · 2021Article
- OXER1 and RACK1-associated pathway: a promising drug target for breast cancer progression.Oncogenesis · 2020Article
- Biomarker heterogeneity between primary breast cancer and synchronous axillary lymph node metastases.Oncology letters · 2020Article
- Article
- Expression of Krüppel-like factor 9 in breast cancer patients and its effect on prognosis.Oncology letters · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is currently the most common form of cancer and the second-leading cause of death from cancer in women. Though considerable progress has been made in the treatment of breast cancer, the heterogeneity of tumors (both inter- and intratumor) remains a considerable diagnostic and prognostic challenge. From clinical observation to genetic mutations, the history of understanding the heterogeneity of breast cancer is lengthy and detailed. Effectively detecting heterogeneity in breast cancer is important during treatment. Various methods of depicting this heterogeneity are now available and include genetic, pathologic, and imaging analysis. These methods allow characterization of the heterogeneity of breast cancer on a genetic level, providing greater insight during the process of establishing an effective therapeutic plan. This study reviews how the understanding of tumor heterogeneity in breast cancer evolved, and further summarizes recent advances in the detection and monitoring of this heterogeneity in patients with breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.